74.98MMarket Cap-1.31P/E (TTM)
3.010High2.750Low200.07KVolume2.950Open2.940Pre Close565.19KTurnover1.03%Turnover RatioLossP/E (Static)26.97MShares18.35052wk High0.45P/B53.94MFloat Cap2.75052wk Low--Dividend TTM19.40MShs Float24.000Historical High--Div YieldTTM8.84%Amplitude2.750Historical Low2.824Avg Price1Lot Size
Alto Neuroscience Stock Forum
The commercial potential is noteworthy for several reasons:
The treatment-resistant depression market represents approximately 30% of MDD patients, creating a substantial addressable market for adjunctive therapies.
The biomarker-guided approach could significantly improve treatment outcomes by identifying likely responders, potentially commanding premium pricing compared to traditional antidepressants.
EEG biomarkers provide an objective, m...
Revolutionary Depression Treatment Patent: How Alto's EEG Biomarker Could Transform Patient Care
Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial
Wednesday, 12th February at 8:03 am
– Interim analysis resulted in a recommendation to continue the study with a total targeted biomarker population of ~200 patients in the final analysis sample –
– Topline results are expected in mid-2026 –
– The company recently reported an estimated preliminary 2024 year-end cash balance of approximately ...
Clinical Trial Success: Alto's Novel Depression Treatment Hits Key Milestone in Phase 2b Study
Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology
Wednesday, 11th December at 8:03 am
– Data generated from Alto's precision psychiatry platform and clinical-stage product candidates highlighted across three poster presentations and a panel discussion –
– New preclinical data from a reverse translation study demonstrates the link between the mechanism of ALTO-300 and the EEG biomarker used for...
<- Blackrock ->
$Alto Neuroscience (ANRO.US)$
sec.gov/Archive...
#myANROanalysis
No comment yet